BridgeBio Pharma Inc

BridgeBio Pharma Inc. is a biopharmaceutical company whose core business model involves the discovery and development of transformative medicines. This process inherently requires extensive animal testing to satisfy regulatory requirements for safety and efficacy prior to human clinical trials. The company's pipeline includes investigational drugs across multiple therapeutic areas, all of which must undergo nonclinical testing protocols that utilize animal models. These activities are conducted under the Animal Welfare Act and results are submitted to the FDA as part of Investigational New Drug (IND) applications.

The provided evidence, including company filings and references to regulatory submissions like NDA 216540, confirms that animal testing is a fundamental and non-negotiable component of BridgeBio's drug development process. While specific numbers of animals used are not detailed in the public excerpts, the company's operations are built upon this standard industry practice. There is no indication in the gathered materials of a corporate policy or commitment to replace, reduce, or refine animal testing through alternative methods.